Piramal Pharma Solutions Formulation Services

Patient Centricity Quick Facts Sheet

Regulatory Services Quick Facts Sheet

Piramal Pharma Solutions Peptides Overview

Vaccines & Biologics Quick Facts Sheet

Biotech Quick Facts Sheet

ADC Quick Facts Sheet

Piramal Pharma Solutions Formulations brochure

Piramal Pharma Solutions Integration Service Offerings Brochure

Piramal Pharma Solutions Global Capabilities Brochure

Antibody-Drug Conjugation (ADC) Services Brochure

Explore our global network of sites and capabilities designed to support your molecule from discovery through commercialization

For over 60 years, our Riverview, Michigan facility has been a global leader in drug substance development and manufacturing, offering comprehensive services from early development to commercialization. This includes specialized solutions for HPAPIs and payload-linkers, enabling Riverview to support complex programs across diverse therapeutic areas. All this – backed by an exceptional regulatory record, a recent facility expansion, and 18 successful API launches. Watch the video to learn why Riverview is the partner your next API program needs.

Meet Conor Barry, Global Head of Bioconjugates Development at Piramal Pharma Solutions (PPS). With over 15 years of scientific experience, Conor shares insights into the rapid evolution of targeted therapeutics and the expanding potential of bioconjugates. Beyond the 15 approved ADCs (Antibody-Drug Conjugates) used in cancer treatment, the field is advancing into applications beyond oncology, including antibody-oligonucleotide conjugates and targeted radiotherapies. As part of the PPS Science Collective, Conor highlights PPS’s commitment to advancing life-changing therapies. Over nearly 20 years, PPS has supported clients in advancing more than 40 bioconjugates into clinical trials and two into commercial production.

ADCelerate is Piramal Pharma Solutions’ rapid approach to delivering Phase-I appropriate ADC drug substance and drug product

Vaccines_and_Biologics_Quick_Facts_Sheet

Generic Peptide APIs Peptides for Toxicology & Clinical Trials

Explore our integrated ADC development and manufacturing services, designed to take your molecule from concept to clinic with speed and precision.

ADCelerate Quick Facts Sheet

Piramal Pharma Solutions (PPS) is a leading global CDMO offering integrated services across the entire drug life cycle, from discovery and development to commercial manufacturing. Through a network of 15 facilities across North America, Europe, and India, PPS provides expertise in APIs, formulations, clinical trial supplies, sterile injectables, HPAPIs, ADCs, peptides, biologics, vaccines, and specialty therapeutics. Backed by over 5,300 employees, robust scientific expertise, and a patient-centric approach, PPS helps pharmaceutical and biotech companies accelerate development timelines, reduce complexity, and bring innovative therapies to patients worldwide through flexible, end-to-end solutions.

Investment plan will add commercial scale sterile injectables capabilities Expansion will significantly increase production capacity and operational efficiency Lexington facility now better capable of supporting increased market demand #piramalpharma,#cdmo,#globalcdmo,#expansion

Each year, we observe Patient Centricity Week during the week of September 17th, aligning with the World Health Organization’s World Patient Safety Day. This annual event serves as a powerful reminder of our shared responsibility to uphold the highest standards of quality and safety in everything we do.

Piramal Pharma Solutions' Aurora facility excels in the process/route selection, process development, and cGMP and non-GMP manufacturing of APIs. With extensive expertise across phases and specialized capabilities for every unique challenge, the Aurora site has successfully launched 15 APIs to date. Watch the video to discover why Aurora is the ideal partner for your next API project!